MediWound (NASDAQ:MDWD) Now Covered by Oppenheimer

Oppenheimer started coverage on shares of MediWound (NASDAQ:MDWD) in a research note published on Monday. The firm issued an outperform rating and a $34.00 price target on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on MDWD. Alliance Global Partners assumed coverage on shares of MediWound in a research note on Friday, May 2nd. They issued a “buy” rating and a $25.00 target price for the company. Wall Street Zen raised shares of MediWound to a “sell” rating in a report on Friday, March 21st. HC Wainwright set a $31.00 price target on shares of MediWound and gave the company a “buy” rating in a report on Thursday, May 22nd. Finally, Craig Hallum assumed coverage on shares of MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 price target on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, MediWound presently has an average rating of “Moderate Buy” and an average price target of $31.80.

MediWound Stock Up 1.3%

MDWD opened at $22.24 on Monday. MediWound has a 52-week low of $12.78 and a 52-week high of $24.00. The company has a 50 day moving average of $18.00 and a two-hundred day moving average of $17.82. The company has a market cap of $240.37 million, a P/E ratio of -7.67 and a beta of 0.30.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.58. The business had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the firm earned ($1.05) earnings per share. Research analysts anticipate that MediWound will post -2.66 earnings per share for the current year.

Institutional Trading of MediWound

Institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp raised its holdings in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after purchasing an additional 70,367 shares during the period. Rhumbline Advisers raised its holdings in shares of MediWound by 7.3% during the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 739 shares during the period. Barclays PLC raised its holdings in shares of MediWound by 11.2% during the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 1,249 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of MediWound by 154.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of MediWound by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company’s stock worth $1,757,000 after purchasing an additional 3,408 shares during the period. 46.83% of the stock is owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.